A safety review into Novartis’ new anti-VEGF drug Beovu has revealed that reported adverse events are consistent with the approved prescribing information after a group of US retinal specialists linked it to a series of vasculitis cases. Read more
University designs slit lamp breath shield prototype
Engineers have developed an expanded breath shield that can be mounted to slit lamps, providing greater protection to eyecare professionals performing urgent and essential care during the COVID-19 crisis. Read more
Protein in blood a direct link to AMD
Scientists have identified a new protein that could help establish improved diagnosis and treatment of age-related macular degeneration (AMD). Read more
WHO calls for eyecare to be part of universal health coverage
The World Health Organization is calling on nations to adopt five key recommendations of its World report on vision, including making eyecare an integral part of universal health coverage. Read more
Safilo secures digital position acquisition of Blenders
Italian eyewear group Safilo has sought to galvanise its portfolio of brands, as well as online sales technology, with the acquisition of San Diego-based eyewear manufacturer and retailer Blenders Eyewear. Read more
Eye filler therapy shows promise with corneal blindness
Scientists have developed an injectable biosynthetic ‘glue filler’ that repairs corneal perforations, potentially removing the need for corneal donations and transplants. Read more
Novartis AMD drug Beovu secures European approval
European drug regulators have followed in the footsteps of their Australian and US counterparts, following the approval of Novartis’ new anti-VEGF therapy. Read more
Warby Parker launches its own contact lens
US-based online retailer of prescription spectacles Warby Parker has entered a new section of the ophthalmic market with its own brand of contact lenses. Read more
Ocular gene therapy begins on the NHS
The UK’s national health provider has started treating patients with Leber’s Congenital Amaurosis (LCA) with a new sight-restoring gene therapy. Read more
US approves first ever treatment for thyroid eye disease
Horizon Therapeutics has had its drug Tepezza, which is the first ever treatment for thyroid eye disease, approved by The US Food and Drug Administration (FDA). Read more